Pharmacogenomics of cholesterol-lowering therapy (Q36335716)

13 August 2017

1 reference

title

Pharmacogenomics of cholesterol-lowering therapy (English)

1 reference

13 August 2017

1 reference

Gerd Schmitz

1

0 references

author name string

Thomas Langmann

series ordinal

2

1 reference

13 August 2017

5 December 2005

1 reference

13 August 2017

Vascular Pharmacology

1 reference

13 August 2017

44

1 reference

13 August 2017

2

1 reference

13 August 2017

75-89

1 reference

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Statin-fibrate combinations in patients with combined hyperlipedemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Lessons learned from statin trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Gemfibrozil greatly increases plasma concentrations of cerivastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Molecular clues into the pathogenesis of statin-mediated muscle toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Safety of statins: focus on clinical pharmacokinetics and drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Sitosterolemia: a gateway to new knowledge about cholesterol metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Lipid-lowering trials in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

HMG-CoA reductase inhibitors and P-glycoprotein modulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Systematic review on the risk and benefit of different cholesterol-lowering interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pharmacogenetic study of statin therapy and cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Comparative effects of lipid-lowering therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Biochemical, physiological and medical aspects of ubiquinone function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Comparative tolerability of the HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Ezetimibe and statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The prevalence of side effects with regular and sustained-release nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

HMG CoA reductase inhibition reduces sarcolemmal Na+–K+ pump density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The genetic determinants of the CYP3A5 polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Coenzyme Q10, Alpha-Tocopherol and Free Cholesterol in HDL and LDL Fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The nicotinic acid receptor--a new mechanism for an old drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Stabilization of atherosclerotic plaques: new mechanisms and clinical targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Cholesterol-lowering agent myopathy (CLAM)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Niacin, lipids, and heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Selenoprotein synthesis and side-effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pharmacological interactions of statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Statin-associated myopathy with normal creatine kinase levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Regulation of reverse cholesterol transport and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Clinical outcomes in statin treatment trials: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

The effects of fibrates on lipoprotein and hemostatic coronary risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Clinical pharmacokinetics of fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Statin-fibrate combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Pharmacogenomics and drug response in cardiovascular disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Muscular side effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

New statins and new doses of older statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Colesevelam hydrochloride.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

HMG-CoA reductase inhibitors and myotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Lovastatin, isoprenes, and myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2allele of the platelet glycoprotein IIIa gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Protein prenylation: molecular mechanisms and functional consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.07.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VPH.2005.07.012

1 reference

release_gh6t5mvdybanxihjlsmq2ln2x4

13 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gh6t5mvdybanxihjlsmq2ln2x4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16337220

1 reference

PubMed ID

16337220